NASDAQ:VERU Veru (VERU) Stock Price, News & Analysis $0.95 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.93▼$0.9750-Day Range$0.78▼$1.4252-Week Range$0.36▼$1.92Volume436,442 shsAverage Volume2.21 million shsMarket Capitalization$138.84 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Veru alerts: Email Address Veru MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside321.7% Upside$4.00 Price TargetShort InterestBearish9.01% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.48Based on 3 Articles This WeekInsider TradingSelling Shares$250,075 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.27) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.69 out of 5 starsMedical Sector698th out of 936 stocksPharmaceutical Preparations Industry326th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingVeru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVeru has only been the subject of 2 research reports in the past 90 days.Read more about Veru's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.01% of the outstanding shares of Veru have been sold short.Short Interest Ratio / Days to CoverVeru has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Veru has recently increased by 25.98%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVeru does not currently pay a dividend.Dividend GrowthVeru does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERU. Previous Next 1.9 News and Social Media Coverage News SentimentVeru has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Veru this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for VERU on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Veru to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veru insiders have sold 1,397.54% more of their company's stock than they have bought. Specifically, they have bought $16,699.00 in company stock and sold $250,075.00 in company stock.Percentage Held by Insiders14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Veru's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Veru are expected to decrease in the coming year, from ($0.27) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veru is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veru is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeru has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Veru's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.I have uncovered a bombshell that changes everything… and threatens everything. About Veru Stock (NASDAQ:VERU)Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.Read More VERU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERU Stock News HeadlinesJuly 2, 2024 | globenewswire.comVeru to Participate in the Leerink Therapeutics Forum: I&I and MetabolismJune 26, 2024 | investorplace.comVERU Stock Earnings: Veru Beats EPS, Misses Revenue for Q1 2024July 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."June 24, 2024 | globenewswire.comVeru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific SessionsJune 18, 2024 | globenewswire.comVeru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024June 17, 2024 | globenewswire.comVeru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of ShareholdersJune 10, 2024 | globenewswire.comVeru to Present at the American Diabetes Association's 84th Scientific SessionsMay 22, 2024 | finance.yahoo.comIndividual investors account for 48% of Veru Inc.'s (NASDAQ:VERU) ownership, while institutions account for 25%July 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."May 22, 2024 | globenewswire.comVeru to Present at the Jefferies Global Healthcare ConferenceMay 17, 2024 | investing.comVeru Inc. CEO sells over $246k in company stockMay 17, 2024 | investing.comVeru Inc. executive buys $9,999 in company stockMay 15, 2024 | globenewswire.comVeru Announces Steven B. Heymsfield M.D.May 14, 2024 | globenewswire.comVeru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology WeekMay 14, 2024 | markets.businessinsider.comBuy Rating for Veru Inc. on Promising Enobosarm Trials and Strategic Market PositioningMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed on Veru Amid Strong Clinical Prospects and Solid Financial PositionMay 9, 2024 | finance.yahoo.comVeru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial RecoveryMay 8, 2024 | msn.comVERU Stock Earnings: Veru Misses EPS, Beats Revenue for Q2 2024See More Headlines Receive VERU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPersonal Products Current SymbolNASDAQ:VERU CUSIP31446210 CIK863894 Webwww.veruhealthcare.com Phone(305) 509-6897Fax312-595-9122Employees230Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+321.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,150,000.00 Net Margins-265.27% Pretax Margin-283.63% Return on Equity-130.13% Return on Assets-67.82% Debt Debt-to-Equity RatioN/A Current Ratio4.72 Quick Ratio4.22 Sales & Book Value Annual Sales$16.30 million Price / Sales8.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book4.31Miscellaneous Outstanding Shares146,380,000Free Float125,597,000Market Cap$138.84 million OptionableOptionable Beta-0.43 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Mitchell S. Steiner F.A.C.S. (Age 63)M.D., Chairman, President & CEO Comp: $885.32kDr. Harry Fisch F.A.C.S. (Age 65)M.D., Vice Chairman & Chief Corporate Officer Ms. Michele Greco (Age 65)CFO & Chief Administrative Officer Comp: $493.7kDr. K. Gary Barnette Ph.D. (Age 56)Chief Scientific Officer Comp: $676.27kMr. Samuel FischExecutive Director of Investor Relations & Corporate CommunicationsMr. Michael J. PurvisExecutive VP, General Counsel & Corporate Strategy and SecretaryMr. Kevin J. Gilbert CPAJ.D., Executive Vice President of Corporate DevelopmentMr. Martin Tayler (Age 55)Executive Vice President of FC2 Global Operations Comp: $180.51kMr. Philip R. Greenberg J.D.Executive VP & Deputy General CounselDr. Domingo Rodriguez M.D. (Age 62)Executive Vice President of Global Clinical Operations More ExecutivesKey CompetitorsNu Skin EnterprisesNYSE:NUSNature's Sunshine ProductsNASDAQ:NATRMedifastNYSE:MEDEstée Lauder CompaniesNYSE:ELInter ParfumsNASDAQ:IPARView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 419,374 shares on 7/26/2024Ownership: 0.303%SeaCrest Wealth Management LLCBought 91,000 shares on 7/22/2024Ownership: 0.082%180 Wealth Advisors LLCBought 28,350 shares on 7/17/2024Ownership: 0.136%Rosalind Advisors Inc.Sold 1,803,997 shares on 7/12/2024Ownership: 1.842%Mitchell Shuster SteinerSold 63,379 sharesTotal: $77,956.17 ($1.23/share)View All Insider TransactionsView All Institutional Transactions VERU Stock Analysis - Frequently Asked Questions How have VERU shares performed this year? Veru's stock was trading at $0.72 at the beginning of the year. Since then, VERU stock has increased by 31.7% and is now trading at $0.9485. View the best growth stocks for 2024 here. How were Veru's earnings last quarter? Veru Inc. (NASDAQ:VERU) announced its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.02. The firm earned $4.14 million during the quarter, compared to the consensus estimate of $3 million. Veru had a negative trailing twelve-month return on equity of 130.13% and a negative net margin of 265.27%. Who are Veru's major shareholders? Veru's top institutional investors include Rosalind Advisors Inc. (1.84%), Bank of New York Mellon Corp (0.30%), 180 Wealth Advisors LLC (0.14%) and SeaCrest Wealth Management LLC (0.08%). Insiders that own company stock include Mitchell Shuster Steiner, Harry Fisch, K Gary Barnette, Mario Eisenberger and Lucy Lu. View institutional ownership trends. How do I buy shares of Veru? Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some other companies that Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI) and Vaxart (VXRT). This page (NASDAQ:VERU) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veru Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veru With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
